OCT-980
RHO-associated autosomal dominant Retinitis Pigmentosa (RHO-adRP)
Phase 1Active
Key Facts
Indication
RHO-associated autosomal dominant Retinitis Pigmentosa (RHO-adRP)
Phase
Phase 1
Status
Active
Company
About Octant Biotech
Octant Biotech is a private, pre-revenue drug discovery company pioneering a platform-based approach to engineer small molecule drugs against complex cellular mechanisms. Its core technology, the Octant Navigator, integrates Generative Biology (high-throughput cellular sensor engineering), Generative Chemistry (nano-scale automated synthesis), and Generative AI in a rapid design-build-test-learn cycle. The company has built a diversified preclinical pipeline targeting genetic, oncology, metabolism, and immunology diseases, with its most advanced candidate, OCT-980 for retinitis pigmentosa, having initiated a Phase 1a study in healthy volunteers in Q1 2026.
View full company profile